Impact of Interventions on Admissional SOFA Score on Clinical Outcomes of Critically Ill Patients

Sponsor
Hospital Sao Domingos (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05790915
Collaborator
(none)
1,000
20

Study Details

Study Description

Brief Summary

Introduction: The SOFA score (Sequential Organ Function Assessment) and its derived measures, such as the Delta SOFA, are used worldwide to determine the severity and prognosis of critically ill patients.

Objectives: The primary objective of this study was to assess the impact of standardized interventions on the six organ dysfunctions of SOFA score on outcomes of critically ill patients through the 48-hour delta SOFA score and 28 days mortality. The secondary outcome measures comprised the evaluation of standardized interventions on ICU and hospital length of stay ; duration of mechanical ventilation and time using vasoactive drugs. Uni and multivariate statistical analysis will be used to determine organ failures associated to outcome.

Methods: Interventional prospective cohort study involving patients admitted to three ICUs of a tertiary hospital from April 01, 2023 to March 31, 2024. Whenever an admission SOFA score ≥ 2 is identified a standardized protocol of interventions is implemented in the therapeutic plan of the patient (Table 1). A new SOFA score after 48 hours will determine the tendency of the SOFA Score (Delta SOFA) and the result will be correlated with the 28-day mortality

Condition or Disease Intervention/Treatment Phase
  • Combination Product: Standardized interventions

Detailed Description

Table 1. SOFA standardized protocol

  1. Respiratory Protective mechanical ventilation; mechanical power < 16, NIV Prevention of PSILI: ROX and HACOR index

  2. Hemodynamic SOSD protocol; Pressoric target; Lactate clearance

  3. Neurologic Image; EEG; Sedation goals

  4. Hematologic Basic disease approach; drugs; DDAVP use

  5. Renal Avoid nephrotoxicity; Avoide hypotension

  6. Hepatic Avoid hepatotoxic drugs; basic disease approach.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of Interventions on Admissional SOFA Score on Clinical Outcomes of Critically Ill Patients
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Group 1

Patients with SOFA score < 2 at admission. No intervention

Group 2

Patients with SOFA score equal to or > 2 on admission and who improved after 48 hours of treatment. Intervention focused on identified organ dysfunction(s)

Combination Product: Standardized interventions
Standardized interventions according organ dysfunction

Group 3

Patients with SOFA score equal to or > 2 on admission and who did not improve after 48 hours of treatment. Intervention focused on identified organ dysfunction(s)

Combination Product: Standardized interventions
Standardized interventions according organ dysfunction

Outcome Measures

Primary Outcome Measures

  1. Impact of standardized interventions in respiratory dysfunction on 48-hour delta SOFA [48 hours]

    Lung protective ventilation: Tidal volume = 6 ml/kg; Plateau pressure < 28 mmHg; driving pressue < 16 cm H2O; Mechanical power < 16 Joules/min; Prevention of self-inflicted lung injury (P-SILI): ROX index > 4.8 and HACOR < 5.

  2. Impact of standardized interventions in hemodinamic dysfunction on 48-hour delta SOFA [48 hour]

    SOSD (salvage, optimization, stabilization and de-escalation ) protocol; mean arterial pressoric taget of at least 65 mm Hg, Lactate serum level < 19 mg/dL.

  3. Impact of standardized interventions in neurologic dysfunction on 48-hour delta SOFA [48 hour]

    Image: cranial CT; Electroencephalografic monitoring and RASS Score between -1 and +1

  4. Impact of standardized interventions in hematologic dysfunction on 48-hour delta SOFA [48 hour]

    Basic disease approach; avoid drugs that interfere with coagulation; Platelet transfusion in case of hemohhage; DDAVP when indicated.

  5. Impact of standardized interventions iin renal dysfunction on 48-hour delta SOFA [48 hour]

    Avoid nephotoxic drugs; Mantain mean arterial blood pressure > 65 mmHg

  6. Impact of standardized interventions in hepatic dysfunction on 48-hour delta SOFA [48 hour]

    Avoid hepatotoxic drugs;basic disease approach

Secondary Outcome Measures

  1. Impact of standardized interventions in respiratory dysfunction on 48-hour delta SOFA [28 days]

    Lung protective ventilation: Tidal volume 6 ml/kg; Pateau pressure < 28 mmHg; driving pressue < 16 cm H2O; Mechanical power < 16 Joules/min; Prevention of self-inflicted lung injury (P-SILI): ROX index > 4.8 and HACOR < 5.

  2. Impact of standardized interventions in hemodinamic dysfuction on 48-hour delta SOFA [28 days]

    SOSD (salvage, optimization, stabilixation and de-escalation ) protocol; mean arterial pressoric taget of at least 65 mm Hg, Lactate serum level < 19 mg/dL.

  3. Impact of standardized interventions in neurologic dysfunction on 48-hour delta SOFA [28 days]

    Image: cranial CT; Electroencephalografic monitoring and RASS Score between -1 and +1

  4. Impact of standardized interventions in hematologic dysfunction on 48-hour delta SOFA [28 days]

    Basic disease approach; avoid drugs that interfere with coagulation; Platelet transfusion in case of hemohhage; DDAVP when indicated.

  5. Impact of standardized interventions iin renal dysfunction on 48-hour delta SOFA [28 days]

    Avoid nephotoxic drugs; Mantain mean arterial blood pressure > 65 mmHg

  6. Impact of standardized interventions in hepatic dysfunction on 48-hour delta SOFA [28 days]

    Avaoid hepatotoxic drugs;basic disease approach

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged above 18 years,

  • Lenght of ICU stay of at least 3 days.

Exclusion Criteria:
  • Pregnant patients

  • End-of-life

  • Patients readmitted to the ICU in the same hospitalization

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Hospital Sao Domingos

Investigators

  • Study Director: JOSE R AZEVEDO, MD, PhD, Hospital Sao Domingos
  • Principal Investigator: BARBARA L RIBEIRO, MD, Hospital Sao Domingos

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
José Raimundo Araujo de Azevedo, ICU Assistent Physician, Hospital Sao Domingos
ClinicalTrials.gov Identifier:
NCT05790915
Other Study ID Numbers:
  • HSD 2023 1
First Posted:
Mar 30, 2023
Last Update Posted:
Mar 31, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by José Raimundo Araujo de Azevedo, ICU Assistent Physician, Hospital Sao Domingos
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2023